Wenhua Zhang
About Wenhua Zhang
Wenhua Zhang, age 55, has served as an independent director of Mountain Crest Acquisition Corp. V since April 2021. He is a Partner at Azia Capital Fund LP (since October 2014) and previously held investment roles at T. Rowe Price, Bain Capital, Harvard Management Company, and Newport Asia LLC; he earned an MBA from the Wharton School in May 2001 .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Mountain Crest Acquisition Corp. (MCAC) | Director | Jan 2020 – Feb 2021 | Not disclosed |
| Mountain Crest Acquisition Corp. II (MCAD) | Director | Oct 2020 – Oct 2021 | Not disclosed |
| Mountain Crest Acquisition Corp. III (MCAE) | Director | Mar 2021 – Feb 2023 | Not disclosed |
| Mountain Crest Acquisition Corp. IV (MCAF) | Director | Mar 2021 – Mar 2024 | Not disclosed |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Azia Capital Fund LP | Partner | Oct 2014 – Present | Private investment firm |
| T. Rowe Price | VP Equity Research (TMT) | Aug 2001 – May 2008 | Buy-side research |
| Bain Capital (Brookside Fund) | Director | Jul 2008 – Dec 2010 | Long/short equity |
| Harvard Management Company | SVP & Portfolio Manager | Feb 2011 – Aug 2012 | Endowment investing |
| Newport Asia LLC | Partner & Portfolio Manager | Oct 2012 – Oct 2014 | Asia growth equities |
| Education | MBA (Wharton) | May 2001 | Finance & tech innovation |
Board Governance
- Independence: Board determined Zhang is “independent” under Nasdaq and SEC rules .
- Committee assignments:
- Audit Committee: Member; committee chaired by Dr. Todd Milbourn .
- Compensation Committee: Chair; committee includes Haight and Milbourn .
- Nominating/Governance: No standing committee; independent directors (including Zhang) recommend nominees when needed .
- Executive sessions: Independent directors hold regularly scheduled meetings with only independent directors present .
Fixed Compensation
| Component | Detail | Amount | Notes |
|---|---|---|---|
| Director cash compensation | None disclosed | — | Company states no executive cash comp; director fees not disclosed . |
| Expense reimbursement | Reimbursement of out-of-pocket board-related expenses | Not capped (subject to cash outside trust) | Reviewed by Audit Committee; payable only if a business combination closes or from cash outside trust . |
| Administrative support agreement | Office/admin fee paid to Sponsor | Up to $10,000/month | Not director pay; corporate overhead arrangement . |
Other Directorships & Interlocks
| Company | Public? | Relationship/Interlock | Tenure |
|---|---|---|---|
| MCAC (PLBY transaction predecessor) | Yes | Shared Mountain Crest sponsor ecosystem | Jan 2020 – Feb 2021 |
| MCAD (Better Therapeutics transaction predecessor) | Yes | Shared Mountain Crest sponsor ecosystem | Oct 2020 – Oct 2021 |
| MCAE (ETAO transaction predecessor) | Yes | Shared Mountain Crest sponsor ecosystem | Mar 2021 – Feb 2023 |
| MCAF (CH AUTO transaction predecessor) | Yes | Shared Mountain Crest sponsor ecosystem | Mar 2021 – Mar 2024 |
Expertise & Qualifications
- Buy-side and portfolio management expertise across global equities and Asia growth strategies .
- Sell-side/buy-side research leadership in TMT sectors .
- MBA in finance and technology innovation (Wharton), supporting compensation and strategy governance work .
- Service across multiple SPAC boards provides transaction process familiarity .
Equity Ownership
| Metric | Oct 10, 2024 | Oct 7, 2025 | |---|---|---|---| | Total shares outstanding | 3,320,221 | 2,902,004 | | Wenhua Zhang – shares beneficially owned | 2,400 | 2,400 | | Ownership % of outstanding | <1% | <1% |
- No disclosure of vested vs. unvested shares, options, or pledged shares for Zhang .
- Founder Shares are held by the Sponsor (controlled by CEO Suying Liu), subject to escrow and release conditions; not owned by Zhang .
Governance Assessment
- Committee leadership: Serving as Compensation Committee Chair and Audit Committee member positions Zhang at the core of pay oversight and financial controls, supporting board effectiveness in a lean SPAC structure .
- Independence and engagement: Board has explicitly designated Zhang independent; independent directors meet in executive session and must approve any business combination, strengthening checks on sponsor-related transactions .
- Ownership alignment: Zhang’s beneficial ownership is 2,400 shares (<1%), which is modest versus Sponsor control (≈71% held via Mountain Crest Global Holdings LLC), limiting personal economic alignment compared to Sponsor interests .
- Related-party exposure: The company relies on Sponsor financing (interest-free promissory notes) and converts Sponsor loans into equity; these were approved by the Audit Committee (on which Zhang serves), requiring continued vigilance on conflicts and fair terms .
- Listing and market risks: Securities currently quoted on OTC (after 2024 Nasdaq delisting risk), triggering potential “penny stock” rules that may impair liquidity and investor confidence around any transaction close .
- Regulatory sensitivity: Company cautions that having a non-U.S. citizen director may invite CFIUS review for certain U.S. targets, potentially delaying or prohibiting combinations under FIRRMA—this is a general board risk factor not tied to a named director .
RED FLAGS
- Sponsor dominance of voting power (~71%) and extensive related-party loans and conversions increase perceived conflicts and pressure to complete a deal rather than liquidate .
- OTC quotation and “penny stock” regime may reduce liquidity and attractiveness as a merger partner; threatens post-close listing requirements for any combined company .
- Repeated extensions of the business combination period and reliance on Sponsor advances heighten timeline and financing dependency risks .
Compensation Committee Analysis
- Composition: All independent directors; Zhang serves as Chair .
- Consultant use: Committee may retain independent compensation consultants, counsel, or advisors; independence of advisors must be considered per NASDAQ/SEC factors .
- Interlocks: None disclosed; committee members have not been officers or employees of the company, and executives did not serve on other entities’ committees that would create interlocks .
Notes on Missing Disclosures
- No explicit disclosure of director meeting attendance rates, board/committee fees, equity grants for directors, or director ownership guidelines .
- No Form 4 insider trading data is provided in these proxy statements; beneficial ownership tables indicate static holdings for directors .